<DOC>
	<DOCNO>NCT00600496</DOCNO>
	<brief_summary>This study conduct determine combination AZD6244 give orally twice day standard dos select chemotherapy safe tolerable cancer patient advance solid tumor . The high tolerated dose AZD6244 combination select chemotherapy evaluate . The study also investigate AZD6244 combination standard chemotherapy absorb , distribute excrete body well length time drug remain body . Initial periodic assessment establish patient response combination therapy .</brief_summary>
	<brief_title>A Phase I , Open-Label , Multi-center Study Assess Safety , Tolerability Pharmacokinetics AZD6244 ( ARRY-142886 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients measurable and/or nonmeasurable disease , lack curative option select chemotherapy agent represent standard care WHO performance status 01 Patients must able swallow AZD6244 capsule Prior treatment MEK inhibitor Participation clinical study last 30 day recover side effect investigational study drug Brain metastases spinal cord compression unless treat stable ( least 1 month ) steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ARRY-142886</keyword>
	<keyword>AZD6244</keyword>
	<keyword>Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Kidney Cancer</keyword>
</DOC>